Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

735
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
735
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

712
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
712

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bone health in neuroendocrine tumors and prognostic implications beyond skeletal metastases.

Frontiers in endocrinology·2026
Same author

Impact of BRAF inhibitors on surgical outcomes in melanoma brain metastases: Evidence from a multicenter observational study.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2026
Same author

Rethinking white matter-tumor interaction: a tractography based analysis of associations between fractional anisotropy and morphometry in the IFOF and arcuate fasciculus.

Journal of neuro-oncology·2026
Same author

Refining surgical decision-making in patients with prolactinomas.

Pituitary·2026
Same author

Correction: Utilization of Neuromuscular Blocking Agents in Acute Brain Injury and Associations with Outcomes: A Post Hoc Analysis of the ENIO Study.

Neurocritical care·2026
Same author

Calcaneal quantitative ultrasound parameters strongly correlate with DXA measurements in patients with acromegaly.

Pituitary·2026

Related Experiment Video

Updated: Dec 20, 2025

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

19.3K

Octreotide-Resistant Acromegaly: Challenges and Solutions.

Giuliana Corica1,2, Marco Ceraudo3, Claudia Campana1,2

  • 1Endocrinology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Therapeutics and Clinical Risk Management
|May 23, 2020
PubMed
Summary

Acromegaly treatment involves surgery, radiation, and medications like somatostatin receptor ligands (SRLs). For patients resistant to first-line therapy, newer strategies and understanding molecular responses are key for effective growth hormone (GH) control.

Keywords:
acromegalybiochemical controlmedical therapyresistancesomatostatin receptor ligands

More Related Videos

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

18.6K
A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice
08:11

A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice

Published on: September 26, 2011

23.5K

Related Experiment Videos

Last Updated: Dec 20, 2025

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

19.3K
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

18.6K
A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice
08:11

A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice

Published on: September 26, 2011

23.5K

Area of Science:

  • Endocrinology
  • Oncology
  • Pharmacology

Background:

  • Acromegaly results from excess growth hormone (GH) and insulin-like growth factor 1 (IGF-1), leading to severe comorbidities.
  • Disease duration correlates with mortality; biochemical control can normalize life expectancy.

Purpose of the Study:

  • To review current literature on acromegaly management.
  • To highlight recent therapeutic strategies for patients resistant to first-line medical therapy.
  • To discuss molecular mechanisms of variable response to first-generation somatostatin receptor ligands (SRLs).

Main Methods:

  • Literature review of current acromegaly treatment strategies.
  • Analysis of therapeutic options for medically resistant acromegaly.
  • Exploration of molecular factors influencing treatment efficacy.

Main Results:

  • Transsphenoidal surgery is a common first-line treatment.
  • First-generation SRLs are standard for persistent disease post-surgery or for non-surgical candidates, but only achieve control in about 50% of patients.
  • Alternative medical therapies include pasireotide, cabergoline, and pegvisomant.

Conclusions:

  • Effective management of acromegaly requires a multi-modal approach including surgery, radiotherapy, and various medical therapies.
  • Understanding patient-specific factors and molecular mechanisms can guide treatment selection for resistant cases.
  • Personalized medical therapy selection is crucial for optimizing outcomes in acromegaly.